Leon Kircik, Dermatology Meeting News 2021: Roflumilast Foam in Scalp and Body Psoriasis
Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai, New York, NY, USA) kindly took the time to speak with us about the results from the recent phase 2b study investigating roflumilast foam in the treatment of scalp and body psoriasis.
His abstract entitled ‘Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A Randomized, Double-blind, Vehicle-controlled Phase 2b Study’ was presented at AAD VMX, 23-25 April.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.
- Can you give us a brief overview of scalp psoriasis, its disease burden and the unmet needs in its treatment? (0:20)
- Could you tell us a little about roflumilast and the aim of your study? (1:10)
- Could you tell us about the design and patient population enrolled in your phase 2b study? (1:33)
- What were the key clinical endpoints measured in the study? (2:17)
- Could you briefly summarize the overall results? (2:28)
Disclosures: Prof. Leon Kircik is a speaker for Galderman, Genetech, Johnson & Johnson, Leo Pharma, 3M Pharmaceuticals, Onset Dermatologics, Pharmaderm, Merck Serano, SkinMedica, Stiefel a GSK company, Triax Pharmaceuticals, Valeant Pharmaceuticals, Warner Chilcott; serves on an advisory board for Galderma, Genetech, Intendis, Johnson & Johnson, NanoBio Corporation, Promius Pharma, LLC, SkinMedica, Stiefel a GSK company, Valeant Pharmaceuticals, Warner Chilcott; is an investigator for Ferndale Laboratories, Galderman, Genetech, GlaxoSmithKline, Healthpoint, Intendis, Johnson & Johnson, Leo Pharma, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, NanoBio Corporation, Novartis Pharmaceuticals, Nucryst, Obagi Medical Products, Onset Dermatologics, Orthro Dermatologics, Promius Pharma, LLC, QLT Inc, Pharmaderm, Pfizer, SkinMedica, Stiefel a GSK company, TolerRx, Triax Pharmaceuticals, LLC, Valeant Pharmaceuticals, Warner Chilcott; is a consultant for Galderma Laboratories, Genetech, Intendis, Johnson & Johnson, Leo Pharma, Medical International Technologies, Merck & Co, Merz Pharmaceuticals, Novartis, Promius Pharma, PuraCap Pharmacetical, SkinMedica, Stiefel a GSK company, Triax Pharmaceuticals, Valeant Pharmaceutical.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Psoriasis
Alan Menter, Dermatology Meeting News 2023: Ixekizumab treatment for patients with moderate-to-severe plaque psoriasis
Ixekizumab is a humanized monoclonal antibody currently approved in patients with moderate-to-severe plaque psoriasis. We caught up with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA) to discuss the aims, design, inclusion criteria and main findings of a post-hoc analysis conducted on trials studying the use of ixekizumab in adult and paediatric patients […]
Alan Menter, Dermatology Meeting News 2023: Clinical presentations and unmet needs of palmoplantar psoriasis
Palmoplantar psoriasis has a significant impact on patients’ quality of life and can be challenging to treat. touchIMMUNOLOGY were delighted to speak with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA), about the prevalence and clinical presentations of palmoplantar psoriasis, its impact on quality of life, and the unmet needs in its treatment. […]
Melinda Gooderham, Dermatology Meeting News 2023: Deucravacitinib efficacy by baseline characteristic in moderate to severe plaque psoriasis
Deucravacitinib is an allosteric tyrosine kinase 2 inhibitor approved for the treatment of moderate to severe plaque psoriasis, a post-hoc analysis of the phase 3 POETYK PSO-1 and PSO-2 trials investigated the efficacy of deucravacitinib by baseline characteristics in this indication. touchIMMUNOLOGY were delighted to speak with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!